2023年6月15日 · Doctors use tumor markers to detect liver cancer, track your response to treatment, and predict your outlook. The most commonly used tumor marker is AFP.

Athough the development of molecular biology has led to the identification of new tumor markers, including proteantigens, cytokines, enzymes and isoenzymes, as well as related genes that can be used in the treatment and prognosis of liver cancer, more tumor markers are required for effective early diagnosis of diseases and monitoring of the ...

Based on available sources, biomarkers can be considered as candidates to diagnose and prognosis of various types of primary liver cancer, from sources such as blood, tissue, mic-RNA, proteome and genes. However, more investigations are required to introduce a biomarker for precise detection of early liver cancer.

2024年5月15日 · Alpha-fetoprotein (AFP) tumor marker test: Tumor markers are released into the blood by organs, tissues, or tumor cells in the body. An increased level of AFP in the blood may be a sign of liver cancer. Other cancers and certain noncancerous conditions, including cirrhosis and hepatitis, may also increase AFP levels.

In the present review we will discuss the clinical utility and foreseen future of HCC biomarkers implicated in surveillance, diagnosis, prognosis, and post-treatment assessment. Keywords: liver cancer, biological, markers. 1. Introduction.

2020年12月1日 · Algorithms/panels comprising multiple biomarkers encompassing heterogeneous pathways in carcinogenesis and tumor biology, and clinical factors associated with risk of HCC such as sex, age, and etiology of liver disease have been developed and undergone validation to improve the sensitivity and specificity of HCC early detection .

The three most common markers are total alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive AFP (AFP-L3) and protein induced by vitamin K absence or antagonist-II (PIVKA-II). Total AFP has the sensitivity of 60% and specificity of 90% for the detection of HCC.

Understanding the markers for liver cancer can play a crucial role in early detection, effective treatment, and better patient outcomes. The field of oncology has advanced significantly in recent years, leading to the identification of several biomarkers that help diagnose liver cancer and monitor its progression.

Studies have shown GPC3 to be a reliable serological and immunohistochemical marker for HCC diagnosis, and a potential target for immunotherapies (5-6). GeneTex’s Glypican-3 antibody [GT2473] (GTX633410) is a cited mouse monoclonal antibody validated for WB, ICC/IF, and IHC-P.

2022年9月13日 · To assess the diagnostic role of HCC tumor markers during pretransplant recipient workup, it is necessary to analyze the expression patterns of serum AFP and PIVKA-II in LT candidates with or without HCC, regardless of background liver diseases.